The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to ...

Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk. Findings from a ...

Although blood test reduces deaths by two for every 1,000 men screened, many could face unnecessary treatment ...

They are genes commonly associated with breast cancer in women, but in fact men who carry certain mutations in their BRCA1 or BRCA2 genes are at higher risk of developing certain types of cancer ...

Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA test results from 450 prostate cancer specimens. The findings suggest that ...

CLINTON, Wash. — James DeLong was 51 years old and physically fit when he received devastating news in 2001: prostate cancer. "I'm swallowing hard because, you know, I was like, well, in five years, I ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...